RxDoctor Payments Data

Tanisha Smith

Adult Health · Baton Rouge, LANPI 1740541440

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (48.4%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. 51 manufacturers reported payments, led by Pfizer at 34.4% of the total. Reporting peaked in 2023 at $4,796 and has fallen 55.9% since, to $2,114 in 2025. Among adult health clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$17,445in general payments, 2019–2025

Across 406 payments — averaging $42.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$6K
  • Novartis$3K
  • Global Blood Therapeutics, Inc.$2K
  • AstraZeneca$716
  • Chiesi USA, Inc.$626
  • Johnson & Johnson$616
  • plus $4K from 45 others

What the payments were for

  • Consulting fees$7965%
  • Speaking & faculty fees$7,68244%
  • Travel & lodging$5143%
  • Food & beverage$8,44448%
  • Education$90%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,445 in reported general payments places this provider in the 95th percentile of 203 adult health providers in Louisiana.

See all adult health providers in Louisiana

Medicare billing

Part B allowed, 2024
$13,327
Medicare patients
24
Services billed
216

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Ferriprox (2 Times A Day)Deferiprone13$465,819
OxbrytaVoxelotor39$408,817
Deferasirox25$6,750
Hydroxyurea71$2,174
Promethazine Hcl36$130
Escitalopram Oxalate22$120
Ibuprofen14$53
Lisinopril11$47

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Chiesi USA, Inc.Ferriprox (2 Times A Day)$626$465,81913 claims
Global Blood Therapeutics, Inc.Oxbryta$2,231$408,81739 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 203 adult health providers in Louisiana.

Other adult health in Baton Rouge

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →